<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have recently demonstrated that <z:chebi fb="19" ids="28790">serotonin</z:chebi> (<z:chebi fb="0" ids="28790">5-HT</z:chebi>) increases the production of type 4 collagen by cultured human mesangial cells </plain></SENT>
<SENT sid="1" pm="."><plain>Here we examined the clinical effects of a <z:chebi fb="0" ids="28790">5-HT</z:chebi>(A2) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> whether it would prevent the development or progression of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We compared the levels of <z:chebi fb="0" ids="27823">5-hydroxyindole-3-acetic acid</z:chebi> (5-HIAA), the major metabolite of <z:chebi fb="0" ids="28790">5-HT</z:chebi>, in 24-h urine samples of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n=110) and <z:mpath ids='MPATH_458'>normal</z:mpath> subjects (n=40) </plain></SENT>
<SENT sid="3" pm="."><plain>We then investigated the effects of 24-month treatment with sarpogrelate <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>, a <z:chebi fb="0" ids="28790">5-HT</z:chebi>(A2) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, on urinary albumin level in 10 type 2 diabetics with <z:mp ids='MP_0002959'>microalbuminuria</z:mp>, compared with not treated control group </plain></SENT>
<SENT sid="4" pm="."><plain>Urinary 5-HIAA in diabetic patients was significantly higher (3.44+/-1.43 mg/day) than in <z:mpath ids='MPATH_458'>normal</z:mpath> subjects (1.62+/-0.50 mg/day, P&lt;0.001), and correlated significantly with <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A1c (r=0.56, P&lt;0.001) and with fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (r=0.37, P&lt;0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Sarpogrelate significantly reduced urinary albumin excretion level within 3 months of commencement of treatment (24.3+/-8.58 mg/g Cr, P&lt;0.05), which was persistently seen during the treatment, while no such change was noted in the control group (32.2+/-13.4 mg/g Cr) </plain></SENT>
<SENT sid="6" pm="."><plain>Our study indicate that high levels of <z:chebi fb="0" ids="28790">5-HT</z:chebi> in type 2 diabetics may be one of the underlying mechanisms of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and that treatment with <z:chebi fb="0" ids="28790">5-HT</z:chebi>(A2) receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> may reduce or inhibit the development of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>